scispace - formally typeset
Open AccessJournal ArticleDOI

Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair

TLDR
It is demonstrated that HCA attenuates the inflammatory response and reparative potential of primary human small airway epithelial and capillary endothelium and induces mitochondrial dysfunction and mesenchymal stem cells promote lung epithelial wound repair via the transfer of functional mitochondria.
Abstract
Acute respiratory distress syndrome (ARDS) is a devastating disorder characterized by diffuse inflammation and edema formation. The main management strategy, low tidal volume ventilation, can be associated with the development of hypercapnic acidosis (HCA). Mesenchymal stem cells (MSCs) are a promising therapeutic candidate currently in early-phase clinical trials. The effects of HCA on the alveolar epithelium and capillary endothelium are not well established. The therapeutic efficacy of MSCs has never been reported in HCA. In the present study, we evaluated the effects of HCA on inflammatory response and reparative potential of the primary human small airway epithelial and lung microvasculature endothelial cells as well as on the capacity of bone marrow-derived MSCs to promote wound healing in vitro. We demonstrate that HCA attenuates the inflammatory response and reparative potential of primary human small airway epithelium and capillary endothelium and induces mitochondrial dysfunction. It was found that MSCs promote lung epithelial wound repair via the transfer of functional mitochondria; however, this proreparative effect of MSCs was lost in the setting of HCA. Therefore, HCA may adversely impact recovery from ARDS at the cellular level, whereas MSCs may not be therapeutically beneficial in patients with ARDS who develop HCA.-Fergie, N., Todd, N., McClements, L., McAuley, D., O'Kane, C., Krasnodembskaya, A. Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome.

TL;DR: Mesenchymal stem cells have been proven to have the same effect as their parent cells combined with their numerous advantages over whole cell administration means that they are a promising candidate for clinical application that merits further research.
Journal ArticleDOI

Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS

TL;DR: In this article, the authors investigated the contribution of mitochondrial dysfunction to the injury of alveolar epithelial and endothelial barriers in acute respiratory distress syndrome and the ability of mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) are considered as a cell-free therapy for ARDS.
Journal ArticleDOI

The Necrobiology of Mesenchymal Stromal Cells Affects Therapeutic Efficacy

TL;DR: Advances in understanding the role of immune effector cells in cell therapy, especially macrophages, suggest that the reprogramming of immunity associated with MSCT has a weighty influence on therapeutic efficacy, and data suggest novel approaches to enhancing the beneficial actions of MSCs.
Journal ArticleDOI

Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease

TL;DR: Preclinical studies testing MSC CM and/or EV as treatment for ALI and other inflammatory lung diseases are focused on, and the clinical application of MSC EV remains promising, primarily due to the ability of EV to maintain the functional phenotype of the parent cell as a therapeutic.
Journal ArticleDOI

Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections

TL;DR: The mechanisms of cytokine storm and lung damage caused by SARS-CoV-2 virus leading to COVID-19 disease are outlined and how mesenchymal stem cells and their secreted EVs can be utilized to tackle this damage by harnessing their regenerative properties, which gives them potential enhanced clinical utility compared to other investigated pharmacological treatments.
References
More filters
Journal ArticleDOI

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
Journal ArticleDOI

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

TL;DR: In patients with acute lung injury and the acute respiratory distress syndrome, mechanical ventilation with a lower tidal volume than is traditionally used results in decreased mortality and increases the number of days without ventilator use.
Journal ArticleDOI

Mechanisms of mitophagy

TL;DR: Mitophagy, the specific autophagic elimination of mitochondria, has been identified in yeast, and in mammals during red blood cell differentiation, mediated by NIP3-like protein X (NIX; also known as BNIP3L).
Journal ArticleDOI

Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury.

TL;DR: This is the first evidence, to the authors' knowledge, that BMSCs protect against ALI by restituting alveolar bioenergetics through Cx43-dependentAlveolar attachment and mitochondrial transfer.
Related Papers (5)